AG
SVA

Advisor Group’s Sinovac Biotech, Ltd SVA Stock Holding History

Advisor Group’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Hold
1,362
– – ﹤0.01% 5670
2019
Q3 		$0 Hold
1,362
– – ﹤0.01% 5628
2019
Q2 		$0 Hold
1,362
– – ﹤0.01% 5572
2019
Q1 		$9K Buy
+1,362
New +$8.95K ﹤0.01% 4450
2016
Q4 		– Sell
-3,900
Closed -$23K – 4862
2016
Q3 		$23K Hold
3,900
– – ﹤0.01% 3078
2016
Q2 		$23K Buy
+3,900
New +$23.9K ﹤0.01% 3003

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

Advisor Group's SVA Position: Q4 2019 in Review

Advisor Group held its Sinovac Biotech, Ltd (SVA) position steady in Q4 2019 at 1,362 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5670.

Advisor Group first reported a position in SVA in Q2 2016 and has held it in 6 quarters since. The position peaked at $23K in Q3 2016. 25 funds tracked by Wall St. Rank hold SVA as of Q4 2019.

  • Advisor Group held 1,362 shares of Sinovac Biotech, Ltd worth $0 as of Q4 2019.
  • Advisor Group left its Sinovac Biotech, Ltd share count unchanged in Q4 2019.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5670 holding.
  • Advisor Group first reported a position in Sinovac Biotech, Ltd in Q2 2016 and has held it in 6 quarters since.
  • Advisor Group's Sinovac Biotech, Ltd position peaked at $23K in Q3 2016.
  • 25 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.